[6]
Institute of Medicine Committee on Understanding Premature B. Assuring Healthy O. The National Academies Collection: Reports fund-ed by National Institutes of Health. Behrman RE, Butler AS, e s; Washington, DC: National Academies Press, 2007.
[16]
Health AIo. Welfare. Oral health and dental care in Australia: Key facts and figures 2012; AIHW: Canberra, 2013.
[21]
Güncü, G.N.; Tözüm, T.F.; Cağlayan, F. Effects of endogenous sex hormones on the periodontium--review of literature. Aust. Dent. J., 2005, 50(3), 138-145.
[26]
Saddki, N.; Bachok, N.; Hussain, N.H.; Zainudin, S.L.; Sosroseno, W. The association between maternal periodontitis and low birth weight infants among Malay women. Community Dent. Oral Epidemiol., 2008, 36(4), 296-304.
[31]
Agueda, A.; Ramón, J.M.; Manau, C.; Guerrero, A.; Echeverría, J.J. Periodontal disease as a risk factor for adverse pregnancy outcomes: A prospective cohort study. J. Clin. Periodontol., 2008, 35(1), 16-22.
[35]
Iheozor-Ejiofor, Z.; Middleton, P.; Esposito, M.; Glenny, A.M. Treating periodontal disease for preventing adverse birth outcomes in pregnant women. Cochrane Database Syst. Rev., 2017, 6(6), CD005297.
[39]
Manrique-Corredor, E.J.; Orozco-Beltran, D.; Lopez-Pineda, A.; Quesada, J.A.; Gil-Guillen, V.F.; Carratala-Munuera, C. Maternal perio-dontitis and preterm birth: Systematic review and meta-analysis. Community Dent. Oral Epidemiol., 2019, 47(3), 243-251.
[40]
Ebersole, J.L.; Holt, S.C.; Cappelli, D. Periodontitis in pregnant baboons: Systemic inflammation and adaptive immune responses and preg-nancy outcomes in a baboon model. J. Periodontal Res., 2014, 49(2), 226-236.
[56]
Mahanonda, R.; Seymour, G.J.; Good, M.F.; Powell, L.W.; Halliday, J.W. Effect of initial treatment of chronic inflammatory periodontal dis-ease on the frequency of peripheral blood T‐lymphocytes specific to periodontopathic bacteria. Oral Microbiol. Immunol., 1991, 6(4), 221-227.
[58]
Califano, J.V.; Best, A.M.; Schenkein, H.A.; Tew, J.G.; Schifferle, R.E. Gunsolley, JC Antibody reactive with Porphyromonas gingivalis sero-types K1-6 in adult and generalized early-onset periodontitis. J. Periodontol., 1999, 70(7), 730-735.
[70]
Laine, M.L.; Van Winkelhoff, A.J.; Appelmelk, B.J. Novel polysaccharide capsular serotypes in Porphyromonas gingivalis. J. Periodontal Res., 1996, 31(4), 278-284.
[74]
Kotz, J.; Chegini, N.; Shiverick, K.T. Lamont, RJ Localization of P. gingivalis in preterm delivery placenta. J. Dent. Res., 2009, 88(6), 575-578.
[75]
Ye, C.; Katagiri, S.; Miyasaka, N.; Kobayashi, H.; Khemwong, T.; Nagasawa, T. The periodontopathic bacteria in placenta, saliva and subgingival plaque of threatened preterm labor and preterm low birth weight cases: A longitudinal study in Japanese pregnant women. Clin. Oral Investig., 2020, 24(12), 4261-4270.
[88]
Riewe, S.D.; Mans, J.J.; Hirano, T.; Katz, J.; Shiverick, K.T.; Brown, T.A. Human trophoblast responses to Porphyromonas gingivalis infection.Mol. Oral Microbiol; , 2010, pp. 252-259.
[89]
Konishi, H.; Urabe, S.; Miyoshi, H.; Teraoka, Y.; Maki, T.; Furusho, H. Fetal membrane inflammation induces preterm birth via toll-like receptor 2 in mice with chronic gingivitis. Reprod. Sci., 2019, 26(7), 869-878.
[129]
Gostner, J.M.; Geisler, S.; Stonig, M.; Mair, L.; Sperner-Unterweger, B.; Fuchs, D. Tryptophan Metabolism and Related Pathways in Psychoneuroimmunology: The Impact of Nutrition and Lifestyle. Neuropsychobiology, 2020, 79(1), 89-99.
[161]
Reyes Ocampo, J.; Lugo Huitrón, R.; González-Esquivel, D.; Ugalde-Muñiz, P.; Jiménez-Anguiano, A.; Pineda, B. Kynurenines with neuro-active and redox properties: Relevance to aging and brain diseases. Oxid. Med. Cell. Longev., 2014, 2014, 646909.
[181]
Census, U.S. Population and Housing Unit Estimates; U.S. Government Printing Office, 2020.
[187]
Group F-NBW. BEST (Biomarkers, EndpointS, and other Tools) Resource. Silver Spring (MD) Bethesda (MD): Food and Drug Administration (US) National Institutes of Health (US); 2016. p. Response Biomarker. , 2016. Dec 22; [Updated 21 Sep 17]
[188]
Group F-NBW. BEST (Biomarkers, EndpointS, and other Tools) Resource. Silver Spring (MD) Bethesda (MD): Food and Drug Administration (US) National Institutes of Health (US); 2016. p. Monitoring Biomarker. , 2016. Dec 22; [Updated 21 Jan 25]
[189]
Group F-NBW. BEST (Biomarkers, EndpointS, and other Tools) Resource. Silver Spring (MD) Bethesda (MD): Food and Drug Administration (US) National Institutes of Health (US); 2016. p. Understanding Prognostic versus Predictive Biomarkers. 2016 Dec 22;